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ABSTRACT
Objective Fungal keratitis is a major ophthalmic public 
health problem, particularly in low- income and middle- 
income countries. The options for treating fungal keratitis 
are limited. Our study aimed to describe the outcomes 
of using chlorhexidine 0.2% eye- drops as additional 
treatment in the management of patients with recalcitrant 
fungal keratitis.
Methods This study was nested within a large cohort 
study of people presenting with microbial keratitis in 
Uganda. We enrolled patients with recalcitrant fungal 
keratitis not improving with topical natamycin 5% and 
commenced chlorhexidine 0.2%. Follow- up was scheduled 
for 3 months and 1 year. The main outcome measures 
were healing, visual acuity and scar size at final follow- up.
Results Thirteen patients were followed in this substudy. 
The patients were aged 27–73 years (median 43 years). 
Filamentous fungi were identified by microscopy of 
corneal scrape samples in all cases. Isolated organisms 
included Aspergillus spp, Fusarium spp, Candida spp, 
Bipolaris spp and Acremoninum spp. At the final follow- 
up, nine patients (75%) had healed; three had vision of 
better than 6/18. Three patients lost their eyes due to 
infection. In the remaining nine cases, corneal scarring 
was variable ranging from 4.6 to 9.4 mm (median 6.6 mm, 
IQR 5.9–8.0 mm); of these five had dense scars, three 
had moderate scars and one had a mild scar. None of 
the patients demonstrated signs of chlorhexidine toxicity 
during the follow- up.
Conclusion Chlorhexidine 0.2% was found to be a 
useful sequential adjunctive topical antifungal in cases of 
fungal keratitis not responding to natamycin 5%, which 
warrants further evaluation.
BACKGROUND
Microbial keratitis (MK) has been described 
as a ‘silent epidemic’, which leads to substan-
tial ocular morbidity, with sight loss, pain and 
stigma.1 It frequently leads to dense corneal 
scarring, or even loss of the eye, especially 
when the infection is severe and/or appro-
priate treatment is delayed. A good outcome 
depends on early appropriate treatment, 
supported by correct identification of the 
causative organism, and careful follow- up.2 3 
In low- income and middle- income countries, 
diagnostic and treatment resources are often 
not readily available and outcomes tend to be 
poor.4
Keratitis can be caused by bacteria, fungi, 
viruses and protozoa. Globally, the incidence 
of fungal keratitis (FK) is currently esti-
mated to be more than one million cases per 
year.5 In tropical and subtropical regions FK 
makes up a substantial proportion of cases. 
For example, our previous work in Uganda 
found that the majority of MK presenting 
in a hospital setting in this country is caused 
by filamentous fungi.6 Compared with other 
infections, patients with FK were more likely 
to have a worse outcome.
The current best evidence indicates that 
topical natamycin 5% is the treatment of 
choice for filamentous FK.7 However, probably 
in common with all ocular antifungal agents, 
Key messages
What is already known about this subject?
 ► Microbial keratitis (MK) is a major ophthalmic pub-
lic health problem, particularly in low- income and 
middle- income countries.
 ► MK is a major cause of blindness in sub- Saharan 
Africa.
 ► A large proportion of MK is due to fungal keratitis.
 ► Natamycin 5% eye- drops is the preferred first- line 
treatment option for fungal keratitis, however, not all 
cases respond well to natamycin.
 ► Other options for treatment of fungal keratitis are 
limited.
What are the new findings?
 ► Patients with recalcitrant fungal keratitis not re-
sponding to natamycin 5% eye- drops responded 
well to an additional chlorhexidine 0.2% eye- drops.
How might these results change the focus of 
research or clinical practice?
 ► Chlorhexidine 0.2% eye- drops could be a viable se-
quential combination option for patients with recal-
citrant fungal keratitis not responding to natamycin 
5%.
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it does not appear to be effective at controlling the infec-
tion in all cases.8 9 In addition, natamycin is currently not 
readily available in many countries in sub- Saharan Africa 
(SSA) and it is relatively expensive. Chlorhexidine 0.2% 
is a widely used antiseptic agent. Chlorhexidine has been 
used in ophthalmology for over 30 years as an eye- drop 
preservative and for sterilising contact lenses, and has 
also been used to treat Acanthamoeba and FK.10–15 Two 
pilot trials comparing chlorhexidine to natamycin were 
suggestive of comparable or possibly greater efficacy than 
natamycin, and that chlorhexidine 0.2% w/v (aqueous 
solution) is safe to use.11 12 Recent studies of the suscepti-
bility patterns of Fusarium spp isolates from patients with 
FK in the Netherlands and Tanzania indicated very good 
fungicidal activity.16
This study, from Uganda, investigated the use of chlor-
hexidine 0.2% w/v (aqueous solution) as a sequential 
combination treatment in a cohort of patients with FK 
who had evidence of progressive disease despite inten-
sive topical natamycin. Outcome data up to 1 year are 
presented.
METHODS
This study is a subgroup of a previously reported cohort 
of 313 people with MK presenting to Mbarara Univer-
sity and Referral Hospital Eye Centre (MURHEC) and 
Ruharo Eye Hospitals (REH) in Mbarara, Uganda.6
Patient and public involvement
Patients or the public were not involved in the design, 
or conduct, or reporting, or dissemination plans of our 
research.
Study participants
MK was defined as loss of corneal epithelium (≥1 mm 
diameter) with underlying stromal infiltrate, associated 
with one or more signs of inflammation (conjunctival 
hyperaemia, anterior chamber inflammatory cells, 
±hypopyon).9 We also included patients presenting 
with a deep corneal abscess (≥1 mm), defined as having 
all the features of MK, but without an epithelial defect. 
We excluded those not willing to participate, those not 
willing to return for follow- up, pregnant women, lactating 
mothers and those aged below 18 years.
Clinical assessment
We documented participant’s basic demographic infor-
mation and ophthalmic history. This included the 
circumstances in which their eye became infected, predis-
posing factors, treatment received and their ‘healthcare 
journey’ before reaching the eye hospital. Presenting 
logarithm of minimum angle of resolution visual acuity 
at 2 m in a dark room was measured using Peek Acuity 
software.17 Participants were examined with a slit lamp to 
assess the anterior segment using a structured protocol, 
including eyelid assessment, corneal ulcer features, ante-
rior chamber (flare, cells, hypopyon shape and size) and 
perforation status. Infiltrate size was determined from the 
greatest diameter of the infiltrate (major axis) and the 
widest perpendicular diameter (minor axis).9 The final 
infiltrate size was then derived as the geometric mean 
of these two diameters.9 The same was repeated after 
fluorescein staining of the ulcer to determine epithelial 
defect sizes. High- resolution digital photographs with 
and without fluorescein staining were taken with a Nikon 
SLR 7200 digital camera with Macro lens.
Laboratory assessment
Corneal scrape specimens were collected from the ulcer 
at a slit lamp or an operating microscope, using 21G 
needles after application of proxymetacaine anaesthetic 
eye- drops 0.5% (Minims Bausch & Lomb). Samples were 
assessed using Gram stain, potassium hydroxide and 
calcofluor white (CFW) preparations and direct inocula-
tion on culture media (blood agar, chocolate agar (HBA), 
potato dextrose agar (PDA) and brain heart infusion 
broth). The number of corneal samples were dependent 
on how much material could be safely scraped from the 
cornea. The order of collection was microscopy, solid and 
then liquid phase media. Media were inoculated in the 
clinic then transported directly to the Mbarara University 
Department of Microbiology laboratory for processing. 
Media were incubated at 35°C–37°C for bacteria for up 
to 7 days and at 25°C for up to 21 days for fungi and 
observed daily. CFW preparations were examined imme-
diately in the side lab at MURHEC using a fluorescence 
microscope (Zeiss Primostar ILED) by the attending 
ophthalmologist.
We followed a previously described approach for 
reporting positive microbiology results.18 Briefly, bacteria 
were identified using routine biochemical tests. Iden-
tification of fungi was according to the macroscopic 
appearance of cultures on PDA and microscopic appear-
ance of conidia and spore- bearing structures. Positive 
culture was growth at the site of inoculation or growth on 
one solid medium consistent with microscopy; or semi-
confluent growth at the site of inoculation on one solid 
medium (if bacteria); or growth of the same organism 
on repeated scraping. If, by microscopy, hyphae were 
observed in corneal tissue, but failed to grow in culture, 
the causative organism was reported as fungal.
A random blood sugar test and HIV counselling and 
testing were offered, as per the Uganda Ministry of Health 
HIV testing protocol. For those who were confirmed as 
HIV positive they were referred to the HIV care centre, 
which is on the hospital site.
Treatment and follow-up
Patients were treated empirically at presentation and 
the treatment choice was reviewed when the microbi-
ology results became available. Patients with FK were 
treated with natamycin 5% eye- drops (Zonat Sunways 
India), those with bacterial keratitis were treated with 
ofloxacin 0.3% eye- drops (Biomedica Remedies- India). 
Patients with fungal infection were treated hourly day 
and night for the first 3 days and then hourly while the 
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patient was awake for 2 weeks. This was changed to 2 
hourly for another 2 weeks and then tapered to four 
times a day until healed. For bacterial infections, patients 
were treated hourly day and night for the first 3 days and 
then reduced to six times a day for a further week. All 
patients with fungal MK were also given ofloxacin 0.3% 
eye- drops four times a day as prophylaxis until all epithe-
lial defects were healed. In addition, those in pain were 
treated with atropine 1% eye- drops (locally formulated) 
and oral paracetamol tablets. Raised intraocular pressure 
was treated with Timolol 0.5% eye- drops (locally formu-
lated). Those with presumed viral keratitis were treated 
with acyclovir 3% eye ointment (CIPLA India) five times 
a day for 3 weeks. Most patients were admitted during the 
first week.
After the initial assessment, patients were scheduled 
to be reassessed on at least day 2, day 7, day 21 and 3 
months, and where possible we also conducted a 1- year 
assessment. Additional assessments were conducted as 
clinically indicated.
Patients with FK who were not improving were given 
topical chlorhexidine gluconate 0.2% as a sequential 
combination treatment option, in addition to the nata-
mycin 5%. The decision to add chlorhexidine was based 
on the clinical judgement of the ophthalmologist at 
the day 7 assessment. Indications included increasing 
epithelial defect, increasing infiltrate size and opacity, 
hypopyon height, increasing inflammation (redness 
and pain), limbal involvement and impending perfora-
tion. The chlorhexidine 0.2% w/v (aqueous solution) 
we used was locally reconstituted from 20% chlorhex-
idine at our facility. The facility has a production unit 
for compounding eye medicine and is certified by the 
Uganda National Drug Authority. Patients on chlorhex-
idine were treated hourly while the patient was awake 
for 2 weeks. This was changed to 2 hourly for another 2 
weeks and then tapered to four times a day until healed.
The main outcome measures were final best- corrected 
vision at 3 months, blindness (<3/60 in the affected eye) 
at 3 months and loss of the eye at 3 months. Scar density 
was also graded as ‘no scar’ (clear cornea), ‘mild scar’ 
(anterior chamber structures clearly visible through 
the scar), ‘moderate scar’ (anterior chamber structures 
vaguely visible through the scar) and ‘dense scar’ (ante-
rior chamber structures completely obscured by the scar).
RESULTS
A total of 313 patients with MK were enrolled in the 
study; 168 (54%) had FK. Of these, 13 people with FK 
had clinical evidence of deterioration while on intensive 
topical natamycin. The demographic and clinical char-
acteristics of the 13 participants are presented in table 1. 
Eight (62%%) were male. Their ages ranged between 
27 and 73 years (median 43 years, IQR 38–57 years). 
Seven reported their main occupation to be farming. We 
were able to follow up seven patients to 1 year and three 
additional patients to 3 months although one had to be 
eviscerated at the end of the 3 months follow- up. One 
patient was lost to follow- up after day 45. Two people had 
such a severe infection that it required evisceration at day 
14. Out of the 13 participants, one person was diabetic 
on insulin and four people were HIV positive (one previ-
ously undiagnosed).
Clinical presentation was variable. One patient had 
good vision (6/6), two patients had moderate vision 
impairment (<6/18 to ≥6/60), two patients had severe 
vision impairment (<6/60 to ≥3/60) and eight patients 
were blind (<3/60). The size of the infiltrate (geomet-
rical mean) ranged from 1.7mm to 9.1 mm (median 
7.1 mm, IQR 4.4–8.3 mm).
All participants had microbiological investigations 
performed at presentation, and all had evidence of 
fungal hyphae on light microscopy of slide samples 
performed on the day of presentation. Cultures were set 
up for all cases, which yielded fungal growth in eleven 
cases (culture positive rate 85%). Of the 11 cases, 10 
were identified while one had ‘unidentified’ fungus. The 
organisms identified are listed in table 1.
The clinical course of each infection is documented in 
online supplemental figure 1, including the indication 
for adding chlorhexidine. Seven had increasing primary 
infiltrate size and/or new endothelial plaque, three had 
new satellite lesions and three had progressive corneal 
thinning with perforation or impending perforation. 
Of note, one patient (case 6), was intolerant to nata-
mycin 5%; this was discontinued and chlorhexidine 0.2% 
continued as monotherapy; in all the others the nata-
mycin was continued. In three patients, chlorhexidine 
was started within 3 days of presentation due to evidence 
of a rapidly progressing disease.
Nine (75%) cases, which had previously been dete-
riorating while on natamycin 5% alone, showed signs 
of responding after the introduction of chlorhexidine 
0.2%, with healing of their ulcers and the resolution of 
inflammatory signs (online supplemental figure 1). At 
the time of the final follow- up, three patients (38.5%) 
had vision better than 6/18. The eyes of three patients 
had to be eviscerated due to the progressive and severe 
nature of their infection despite maximum medical treat-
ment. Scar sizes were available for 8 patients, they ranged 
from 4.6 to 9.4 mm (median 6.6 mm, IQR 5.9–8.0 mm). 
Five patients had dense scars, three moderate scars and 
one had mild scars.
DISCUSSION
FK is a severe and potentially blinding corneal infection.4 
The burden is greatest in tropical and subtropical coun-
tries, probably due to a combination of climate (higher 
temperatures and humidity) and frequent agriculture 
related eye injuries.19 FK is responsible for between 20% 
and 60% of corneal infections diagnosed in tropical 
regions.20 Our previous work in Uganda found that fila-
mentous fungi accounted for 62% of corneal infections.6 
It is often inadequately treated with significant barriers to 
receiving appropriate, timely intervention, compounded 
by indiscriminate and inappropriate use of conventional 
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medicines such as topical corticosteroids or harmful 
traditional eye medicines.4 6
There are a limited number of antifungals available 
for treating FK, which fall into four main groups: imid-
azoles, triazoles, polyenes and fluorinated pyrimidines. 
There have been several clinical trials comparing treat-
ment options for FK, which have been systematically 
reviewed.21 22 Natamycin, which was approved in the 1960s 
by the FDA for FK, has been compared with a number 
of newer agents, including voriconazole. Natamycin and 
voriconazole have been compared in four trials, with the 
meta- analysis favouring natamycin.9 21–24
As a result, first- line management of filamentous FK is 
usually with topical natamycin 5% when this is available. 
This was added to the WHO Essential Medicines List in 
2017 for this indication. However, even when intensive 
topical natamycin is initiated, infections frequently prog-
ress relentlessly to perforation and loss of the eye.4 6 7 9 
Moreover, in many countries antifungal eye- drop treat-
ments are simply not available. This includes most 
countries in SSA, some Asian countries and some coun-
tries in Europe.4 25 Natamycin is relatively expensive even 
if it is available. Therefore, additional alternative and 
more affordable drugs are clearly needed if the outcome 
of these infections is to improve.
Our study used chlorhexidine 0.2% as a sequential 
additional treatment for FK which was progressing 
on natamycin 5% monotherapy. We found that most 
patients responded well. These results correlate with 
other studies that have shown that chlorhexidine can 
be used in the management of FK.11 Two early trials in 
South Asia compared topical natamycin and chlorhex-
idine.11 12 These were relatively small, with a combined 
size of 130 participants. In the first trial, three different 
concentrations of chlorhexidine (0.05%, 0.1% and 0.2%) 
were compared with natamycin 5%.12 There were trends 
towards more favourable responses by 5 days and ‘cure’ 
at 21 days with increasing chlorhexidine concentration. 
The authors observed that a chlorhexidine concentra-
tion of 0.2% was superior to natamycin 5% in curing FK. 
In the second trial, chlorhexidine 0.2% was compared 
with natamycin 2.5% (half the standard concentra-
tion).11 Chlorhexidine 0.2% was associated with more 
favourable responses at 5 days. In a meta- analysis of these 
two studies, combining the chlorhexidine and natamycin 
groups with different concentrations, there was a non- 
significant trend favouring chlorhexidine over natamycin 
for cure/healing at 21 days.21
Natamycin is a fungicidal and fungistatic polyene 
antifungal drug that binds to ergosterol but without perme-
abilising the cell membrane like the other polyenes.26 
It also enters the cell and causes cellular toxicity by 
disrupting the ergosterol- dependent membrane metab-
olism.26 Chlorhexidine is a broad- spectrum biocide 
effective against Gram- positive bacteria, Gram- negative 
bacteria, fungi and viruses. It kills by disrupting cellular 
membranes resulting in leakage of cytoplasmic compo-
nents, and formation of irreversible precipitates with 
intracellular ATP and nucleic acids.27 Unlike other anti-
fungal agents which are fungistatic and do not kill the 
fungus, chlorhexidine is fungicidal.28–30
Oliveira et al recently tested fungal sensitivities of chlor-
hexidine, amphotericin B, voriconazole, posaconazole, 
miconazole, natamycin, 5- fluorocytosine and caspofungin 
in isolates collected from patients with FK in Tanzania 
and the Netherlands (all Fusarium spp).16 In that study, 
chlorhexidine showed broad in vitro activity against all 
Fusarium species tested and, compared with the other 
antifungal agents, showed the broadest fungicidal activity 
against the two species tested (90% of Fusarium oxysporum 
strains and 100% of the Fusarium solani strains).16 In this 
report, the median MICs (total MIC range) of chlor-
hexidine in comparison with natamycin were 16 (8-32)
mg/L vs 8 (4-16)mg/L for F.solani spp, 8 (2–64) mg/L 
vs 8 (4–8)mg/L for F. oxysporum spp, 8 (4–64) mg/L vs 
8 (2–8)mg/L for F. fujukuroi spp and 8 (4–16)mg/L vs 4 
(2–16)mg/L for F. dimerum spp. A more recent case series 
from the Netherlands also reported MICs isolates from 
four patients with FK (all Fusarium spp) as ranging from 
2 to 32 mg/L.31 The Mycotic Treatment Trial I (MUTT I) 
also reported the MICs of natamycin for the 256 patients 
who had fungal culture results.32 The reported nata-
mycin MIC ranged from 2 to 32 mg/L for Fusarium spp 
and from 8 to 64 mg/L for Aspergillus flavus.32 In another 
report from China, the MIC for natamycin for 216 strains 
from patients with FK were 8, 32 and 4 mg/L for Fusarium 
spp, Aspergillus spp and Alternaria alternata, respectively.33 
These MICs corresponded to a range of 0.002–0.012 for 
chlorhexidine and 0.001–0.012 for natamycin; somewhat 
below the available eye- drop formulations of chlorhexi-
dine 0.02% or 0.2% and natamycin 2.5% or 5%.
Except for one case who reported severe intolerance to 
natamycin 5% (case 5), chlorhexidine 0.2% was used as a 
sequential adjuvant drug in combination with natamycin 
5%. Even when used as monotherapy, the patient had a 
good response to treatment. One patient with Candida 
(case 9) experienced a rapid deterioration with eventual 
eye loss. Yeast keratitis is not known to respond favour-
ably to natamycin and Chlorhexidine.34 This particular 
patient was a previously undiagnosed HIV positive 
patient, he presented a few weeks later with another 
infiltrate in his only remaining eye which we successfully 
treated with topical amphotericin B 0.15%.35
Strengths and weaknesses
There have not been any reports on using chlorhexidine 
as a sequential combination agent in treatment of recalci-
trant FK in sub- Saharan Africa. The chlorhexidine 0.2% 
was locally produced in our facility making it an easily 
and readily available option and much cheaper than 
natamycin 5% (US$1 compared with US$15). We had 
a good culture sensitivity yield of 85%, which compares 
favourably to other reports from the region which typi-
cally a 50% yield.4 19 36
This report suggests that chlorhexidine may be a bene-
ficial additional treatment for FK. There might have been 
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other reasons why the patients initially did not respond 
to natamycin in our study, such as poor compliance to 
the medicine and having non- fungal coinfection which 
chlorhexidine could have helped treat due to its broad 
antimicrobial (bacterial, fungal and protozoal) activity. 
However, in our cohort, all FK patients were treated with 
ofloxacin (a broad- spectrum antibiotic) from presenta-
tion, in addition to the natamycin. Therefore, untreated 
coinfection is unlikely. Moreover, the proportion of 
patients diagnosed with mixed infection in our cohort 
was only 5%.6 In addition, all the patients were given 
proper counselling on adherence which was particularly 
reinforced in the context of possible treatment failure. 
However, we did not have more objective methods of 
assessing compliance such as weighting the bottles.
Based on their mechanism of action, it is plausible 
that there might be a synergistic effect from a combined 
natamycin and chlorhexidine therapy. Being a smaller 
molecule than natamycin, chlorhexidine may be able 
to penetrate the cornea better, although topical treat-
ment with both drugs has been shown not to result in 
high concentrations in the anterior chamber.37 A recent 
in vitro study from China has suggested that a dual 
therapy of voriconazole and chlorhexidine may be more 
efficacious than a combination of natamycin and chlor-
hexidine.38 However, caution is required in extrapolating 
in vitro result such as this to clinical practice as there is 
often a disconnect between in vitro activity and the in 
vivo response, as highlighted in the MUTT1 study, where 
natamycin was found to be superior to voriconazole.
This was a relatively small series, and the evidence 
needs to be interpreted with caution. Although we did 
not systematically collect toxicity data in this study, most 
of the patients healed with clear peripheral cornea. No 
patients in our study had chlorhexidine discontinued 
because of stinging, allergy or corneal toxicity to the 
chlorhexidine. Due to the resource- limited settings, we 
were not able to set up sensitivity studies for the fungal 
cultures.
CONCLUSION
Chlorhexidine 0.2% appears to be an effective sequen-
tial combination agent to topical antifungal treatment, 
which can be considered in cases of recalcitrant FK not 
responding to natamycin 5% alone.
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